ONCOGENEX Aktie

10,34 EUR 0,0000%

Zu Ihrem Onlinebroker

kaufen verkaufen

ONCOGENEX Aktienkurs : 25.05. ( 15 Min. verzögert)
10,34 € Letzter Kurs	0,00% Veränderung	10,34 € Vortag	10,34 € Eröffnungskurs

mehr Informationen

Hoch/Tief		Volumen		Geldkurs	Briefkurs
10,34 - 10,34 Tag	13,15 - 6,89 52 Wochen	0 Tag	2 Ø 52 Wochen	0,0000000 0 Stücke	0,0000000 0 Stücke

ONCOGENEX Aktienkurs

Wollen Sie wissen, wie es mit dieser Aktie weitergeht?
Wir informieren Sie kostenlos.

Erhalten Sie außerdem Expertenanalysen von:
Gevestor Täglich und John Gossens Daily DAX

16.05.

Isis Pharmaceuticals' Management Presents at Bank of America Merrill Lynch ...

In addition to that we have two drug being developed by partners OGX-011 being developed by OncoGenex and Teva for prostate cancer. It's in the Phase 3 clinical trial. They'll update it next year which could successful...
15.05.

IntegenX Names Biotechnology Veteran David V. Smith Chief Operating Officer

Mr. Smith is currently chair of the Audit Committee and a Director of OncoGenex Pharmaceuticals, Inc. and was previously chair of the Audit Committee and a Director of Perlegen Sciences, Inc. He holds a...

08.05.

Isis Reports Financial Results and Highlights for First Quarter 2012

OncoGenex reported preliminary positive Phase 1 data at the American Society of Clinical Oncology showing that treatment with OGX-427 produced a trend toward increased tumor cell death in patients wi…
07.05.

Tang Capital's Holdings: Insights Into Successful Investing

PK), Spectrum Pharmaceuticals (SPPI), OncoGenex (OGXI) and AP Pharma (APPA.OB). On April 23rd, AstraZeneca announced the acquisition of Ardea Biosciences for $1.26 billion, or about...
04.05.

Isis Pharmaceuticals' CEO Discusses Clinical Development Plans for ISIS ...

Also our partners at OncoGenex and Teva are continuing to enroll patients in the Phase 3 study for OGX-011 in prostate cancer and plan to...

weitere News, die den ONCOGENEX Aktienkurs bewegen

Branche	Pharma
Anzahl Aktien	13,92 Mio.

Boersennews.de